Observational studyInternational journal of clinical oncology2025

The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma.

Hiroaki Nagata et al.PubMed ↗Publisher ↗

No numbers read from the abstract.